PTCH1 and nevoid basal cell carcinoma syndrome: Another class of patients that benefices from Hh inhibitors are individuals with nevoid basal cell carcinoma syndrome (NBCCS) (also referred as nevoid BCC syndrome, Gorlin syndrome, or Gorlin Goltz syndrome, OMIM#109400), an autosomal dominant rare hereditary condition frequently due to germline mutation of PTCH1 gene lacking significant genotype-phenotype correlations [22,23,24].